Literature DB >> 22669353

Longitudinal change in dysarthria associated with Friedreich ataxia: a potential clinical endpoint.

Kristin M Rosen1, Joanne E Folker, Adam P Vogel, Louise A Corben, Bruce E Murdoch, Martin B Delatycki.   

Abstract

CNS functions that show change across short periods of time are particularly useful clinical endpoints for Friedreich ataxia. This study determined whether there is measurable acoustical change in the dysarthria associated with Friedreich ataxia across yearly intervals. A total of 29 participants diagnosed with Friedreich ataxia were recorded across 4 years at yearly intervals. A repeated measures ANOVA was used to determine which acoustic measures differed across time, and pairwise t tests were used to assess the consistency of the change across the time intervals. The relationship between the identified measures with perceptual severity was assessed with stepwise regression. Significant longitudinal change was observed with four measures that relate to the utterance duration and spectral changes in utterances. The spectral measures consistently detected change across time intervals of two or more years. The four measures combined moderately predicted perceptual severity. Together, the results implicate longitudinal change in speaking rate and utterance duration. Changes in speech associated with Friedreich ataxia can be measured across intervals of 2 years and therefore show rich potential for monitoring disease progression and therapy outcomes.

Entities:  

Mesh:

Year:  2012        PMID: 22669353     DOI: 10.1007/s00415-012-6547-x

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  37 in total

1.  A comparison of equal-appearing interval scaling and direct magnitude estimation of nasal voice quality.

Authors:  R I Zraick; J M Liss
Journal:  J Speech Lang Hear Res       Date:  2000-08       Impact factor: 2.297

2.  Effect of level of presentation to listeners on scaled speech intelligibility of speakers with dysarthria.

Authors:  Yunjung Kim; Christina Kuo
Journal:  Folia Phoniatr Logop       Date:  2012       Impact factor: 0.849

3.  Discriminating dysarthria type from envelope modulation spectra.

Authors:  Julie M Liss; Sue LeGendre; Andrew J Lotto
Journal:  J Speech Lang Hear Res       Date:  2010-07-19       Impact factor: 2.297

4.  How is disease progress in Friedreich's ataxia best measured? A study of four rating scales.

Authors:  M C Fahey; L Corben; V Collins; A J Churchyard; M B Delatycki
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-10-20       Impact factor: 10.154

5.  Dysarthric symptomatology of Friedreich's ataxia.

Authors:  Y Joanette; J G Dudley
Journal:  Brain Lang       Date:  1980-05       Impact factor: 2.381

6.  An acoustic study of the relationships among neurologic disease, dysarthria type, and severity of dysarthria.

Authors:  Yunjung Kim; Raymond D Kent; Gary Weismer
Journal:  J Speech Lang Hear Res       Date:  2010-09-30       Impact factor: 2.297

7.  Ataxic dysarthria.

Authors:  R D Kent; J F Kent; J R Duffy; J E Thomas; G Weismer; S Stuntebeck
Journal:  J Speech Lang Hear Res       Date:  2000-10       Impact factor: 2.297

8.  Parametric quantitative acoustic analysis of conversation produced by speakers with dysarthria and healthy speakers.

Authors:  Kristin M Rosen; Raymond D Kent; Amy L Delaney; Joseph R Duffy
Journal:  J Speech Lang Hear Res       Date:  2006-04       Impact factor: 2.297

9.  Spectral measures of the effects of Friedreich's ataxia on speech.

Authors:  Kristin M Rosen; Joanne E Folker; Bruce E Murdoch; Adam P Vogel; Louise M Cahill; Martin B Delatycki; Louise A Corben
Journal:  Int J Speech Lang Pathol       Date:  2010-11-09       Impact factor: 2.484

10.  Automatic method of pause measurement for normal and dysarthric speech.

Authors:  Kristin Rosen; Bruce Murdoch; Joanne Folker; Adam Vogel; Louise Cahill; Martin Delatycki; Louise Corben
Journal:  Clin Linguist Phon       Date:  2010-02       Impact factor: 1.346

View more
  7 in total

Review 1.  Consensus Paper: Neurophysiological Assessments of Ataxias in Daily Practice.

Authors:  W Ilg; M Branscheidt; A Butala; P Celnik; L de Paola; F B Horak; L Schöls; H A G Teive; A P Vogel; D S Zee; D Timmann
Journal:  Cerebellum       Date:  2018-10       Impact factor: 3.847

2.  Dysphagia and swallowing-related quality of life in Friedreich ataxia.

Authors:  Adam P Vogel; Sophie E Brown; Joanne E Folker; Louise A Corben; Martin B Delatycki
Journal:  J Neurol       Date:  2013-12-27       Impact factor: 4.849

3.  Coordination and timing deficits in speech and swallowing in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS).

Authors:  Adam P Vogel; Natalie Rommel; Andreas Oettinger; Lisa H Stoll; Eva-Maria Kraus; Cynthia Gagnon; Marius Horger; Patrick Krumm; Dagmar Timmann; Elsdon Storey; Ludger Schöls; Matthis Synofzik
Journal:  J Neurol       Date:  2018-07-02       Impact factor: 4.849

4.  Oral mobility reflects rate of progression in advanced Friedreich's ataxia.

Authors:  Stéphanie Borel; Peggy Gatignol; Mustapha Smail; Marie-Lorraine Monin; Claire Ewenczyk; Didier Bouccara; Alexandra Durr
Journal:  Ann Clin Transl Neurol       Date:  2019-08-25       Impact factor: 4.511

5.  Home-based biofeedback speech treatment improves dysarthria in repeat-expansion SCAs.

Authors:  Adam P Vogel; Lisa H Graf; Michelle Magee; Ludger Schöls; Natalie Rommel; Matthis Synofzik
Journal:  Ann Clin Transl Neurol       Date:  2022-06-21       Impact factor: 5.430

6.  A Longitudinal Evaluation of Speech Rate in Primary Progressive Apraxia of Speech.

Authors:  Rene L Utianski; Peter R Martin; Holly Hanley; Joseph R Duffy; Hugo Botha; Heather M Clark; Jennifer L Whitwell; Keith A Josephs
Journal:  J Speech Lang Hear Res       Date:  2021-01-21       Impact factor: 2.297

7.  Automatic Evaluation of Speech Rhythm Instability and Acceleration in Dysarthrias Associated with Basal Ganglia Dysfunction.

Authors:  Jan Rusz; Jan Hlavnička; Roman Čmejla; Evžen Růžička
Journal:  Front Bioeng Biotechnol       Date:  2015-07-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.